To activate T cells, DCs take up, process, and present antigens as part of major histocompatibility complexes (MHCs) that interact with T cell receptors. Therefore, Curtis and her team set out to ...
Basal cell carcinoma has low immunogenicity. Tumor cells express Foxc1 protein (red), which suppresses HLA class I (green) in the tumor cells. Compromised antigen presentation ranks among the top ...
CD8 + cytotoxic T lymphocytes (CTLs) serve as central effectors in cancer immunotherapy by directly eliminating tumor cells. However, current clinical therapies face significant limitations. These ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results